(E)-1-(4-methylstyryl)-3,5-bis(trifluoromethyl)benzene | 1173280-49-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-1-(4-methylstyryl)-3,5-bis(trifluoromethyl)benzene
• 英文别名: [2-(4-methylphenyl)-(E)-ethenyl]-3,5-di-(trifluoromethyl)-benzene；1-[(E)-2-(4-methylphenyl)ethenyl]-3,5-bis(trifluoromethyl)benzene
• CAS: 1173280-49-3
• 化学式: C₁₇H₁₂F₆
• 分子量: 330.273
• InChiKey: NKHGADIHVIQBQG-VOTSOKGWSA-N

物化性质

• 熔点：
  101-103 °C(Solv: toluene (108-88-3))
• 沸点：
  313.3±37.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (E)-1-(4-methylstyryl)-3,5-bis(trifluoromethyl)benzene 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 72.0h， 以59%的产率得到[2-(4-bromomethylphenyl)-(E)-ethenyl]-3,5-di-(trifluoromethyl)-benzene
  参考文献：
  名称：

  对官能化的[5]-和[6]碳杂戊烯的光化学合成的研究

  摘要：

  据报道，通过不对称双-对-苯乙烯类化合物的氧化光环化反应，可获得不对称螺旋薄荷基酯的有效途径。发达的路线允许在环A，E或F上引入官能团，并且已经研究了取代基图案对光化学反应的影响。当使用以70:30的异构体比率合成的二薄荷基螺旋烯酯进行双重手性诱导策略时，观察到非对映选择性。

  DOI：

  10.1021/jo900785k
• 作为产物：
  描述：

  3,5-双三氟甲基苯甲醛 、 (4-甲基苄基)三苯基溴化膦 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 以81%的产率得到(E)-1-(4-methylstyryl)-3,5-bis(trifluoromethyl)benzene
  参考文献：
  名称：

  对官能化的[5]-和[6]碳杂戊烯的光化学合成的研究

  摘要：

  据报道，通过不对称双-对-苯乙烯类化合物的氧化光环化反应，可获得不对称螺旋薄荷基酯的有效途径。发达的路线允许在环A，E或F上引入官能团，并且已经研究了取代基图案对光化学反应的影响。当使用以70:30的异构体比率合成的二薄荷基螺旋烯酯进行双重手性诱导策略时，观察到非对映选择性。

  DOI：

  10.1021/jo900785k

文献信息

• Lipids as versatile solvents for chemical synthesis
  作者：Ashot Gevorgyan、Kathrin H. Hopmann、Annette Bayer

  DOI：10.1039/d1gc02311j

  日期：——

  Development of safe, renewable, cheap and versatile solvents is a longstanding challenge in chemistry. We show here that vegetable oils and related systems can become prominent solvents for organic synthesis. Suzuki–Miyaura, Hiyama, Stille, Sonogashira and Heck cross-couplings proceed with quantitative yields in a range of vegetable oils, fish oil, butter and waxes used as solvents. Appropriate methodologies

  开发安全、可再生、廉价且用途广泛的溶剂是化学领域的一项长期挑战。我们在这里展示了植物油和相关系统可以成为有机合成的主要溶剂。Suzuki–Miyaura、Hiyama、Stille、Sonogashira 和 Heck 交叉偶联在一系列用作溶剂的植物油、鱼油、黄油和蜡中进行定量产率。介绍了适用于植物油和相关脂质的高通量筛选和可持续分离技术的适当方法。
• [EN] ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING<br/>[FR] ANALOGUES DE LA FÉXARAMINE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2015138969A1

  公开（公告）日：2015-09-17

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  揭示了具有化合物配方实施例的小说化合物，制备方法的实施例，以及包含它们的组合物。还揭示了一种治疗或预防受试者代谢紊乱的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者的代谢紊乱。此外还揭示了一种治疗或预防受试者肠道区域炎症的方法实施例，包括向受试者（例如，通过胃肠道）施用所述化合物的一种或多种治疗有效量，从而激活肠道中的FXR受体，并治疗或预防受试者肠道区域的炎症。
• Plasminogen Activator Inhibitor-1 Inhibitor
  申请人：Muto Susumu

  公开号：US20070276011A1

  公开（公告）日：2007-11-29

  A medicament having inhibitory activity against plasminogen activator inhibitor-1, which comprises as an active ingredient a compound represented by the following general formula (I) or a salt thereof: wherein R 1 and R 2 represents an aromatic group which may be substituted, W represents a group selected from the following connecting group W-1: (wherein a bond at the left end binds to the carbon atom and a bond at the right end binds to the nitrogen atom, X represents sulfur atom or NH, Y represents oxygen atom or sulfur atom, R 3 represents a hydrocarbon group, hydroxy group, or carboxy group), Z represents a single bond or a connecting group wherein a number of atoms in a main chain is 1 to 3.

  一种具有抑制纤溶酶原激活物抑制剂-1活性的药物，其包含以下通式（I）或其盐作为活性成分的化合物：其中R1和R2代表可以被取代的芳香基团，W代表以下连接基团之一：（其中左端的键结合到碳原子，右端的键结合到氮原子，X代表硫原子或NH，Y代表氧原子或硫原子，R3代表烃基团，羟基或羧基），Z代表单键或连接基团，其中主链中的原子数为1到3。
• ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：US20170066724A1

  公开（公告）日：2017-03-09

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
• [EN] ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING<br/>[FR] ANALOGUES DE LA FEXARAMINE ET LEUR PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2017078927A1

  公开（公告）日：2017-05-11

  Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.